A Phase II, Randomized, Double-Blind, Placebo-controlled, Multi-Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of JTT-654 Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2013
At a glance
- Drugs JTT 654 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 14 Jan 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Oct 2009 New trial record